Clinical Trials in the EU / 2026-526654-14-01
Authorised, recruiting
Phase III
A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
2026-526654-14-01 · tracked via the Priya Life Science EU tracker
Condition studied
Newly Diagnosed Multiple Myeloma
Investigational medicinal product(s)
Lenalidomide Mylan 20 mg hard capsulesLenalidomide Accord 5 mg hard capsulesLenalidomide Accord 25 mg hard capsulesLenalidomide Mylan 5 mg hard capsulesLenalidomide Mylan 25 mg hard capsulesVELCADE 3.5 mg powder for solution for injectionBortezomib injectionpowderlyophilizedfor solutionFortecortin® 2 mg TablettenDexamethason 8 mg GALEN TablettenLenalidomide Mylan 15 mg hard capsulesJNJ-79635322Lenalidomide Accord 15 mg hard capsulesLenalidomide Accord 10 mg hard capsulesLenalidomide Mylan 10 mg hard capsulesDARZALEX 1800 mg solution for injectionLenalidomide Accord 20 mg hard capsules
Eligibility
Primary endpoint
PFS as assessed by a validated computerized algorithm: time from randomization to confirmed progressive disease (per IMWG response criteria) or death, whichever occurs first., 12-month MRD-negative CR rate: complete response or better (per IMWG response criteria) and MRD negative status, at the analysis time window of 12 months, prior to progressive disease or subsequent antimyeloma therapy (including autologous stem cell transplant)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-526654-14-01 on CTIS ↗ ← All trials in the EU